Article Data

  • Views 427
  • Dowloads 131

Original Research

Open Access

Study on the relationship between the structure and functions of anti-human cervical cancer single-chain antibody and the lengths of linkers

  • J. Cheng1
  • Q.X. Du1,*,
  • X.L. Zhang2
  • Y.F. Ren3
  • B.A. Zhang4
  • X.D Feng4

1Department of Gynaecology, People's Hospital of Zhengzhou, Zhengzhou, China

2Henan Provincial People's Hospital, Zhengzhou, China

3Department of Chinese Internal Medicine, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China

4Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

DOI: 10.12892/ejgo2816.2016 Vol.37,Issue 2,April 2016 pp.171-177

Published: 10 April 2016

*Corresponding Author(s): Q.X. Du E-mail:


Background: This study aimed to find the linker with minimal impact among chains to fight against the structure and function of cervical cancer (CC) single-chain antibody. Materials and Methods: The original variable region of heavy chain (VH) and variable region of light chain (VL), and the single-chain antibody with linkers of different lengths (n = 1~8) were modeling by homologous modeling, while the peptide chain structure of (Gly4Ser)n was utilized by the linkers. Comparison of the similarity of original VH/VL and VHn/VLn was carried out by applying the algorithm of spatial hierarchical alignment based on the spherical coordinates. The fore and aft distance and diffusion radius of alpha (α) were also calculated. The stability of antibody with different linker length was then compared. ELISA method was adopted to evaluate the immunological activity of single-chain antibody with different linkers. MTT assay was used to analyze the inhibition effect of ScFv-n on CC cells. Results: When n = 4, the structures were the most similar between ScFv and the original VH/VL. When n = 3, the influence of adding connecting peptide on the stability of single-chain antibody was the least. The result of ELISA and MTT methods indicated that when n = 3, single-chain antibody gained the highest activity. Conclusion: The optimum length of linker of anti-human CC single-chain antibody was n = 3 from the point of mathematical modeling and biology experiments. This study provided new ideas for the design and constructions of single-chain antibody, and theoretical basis for the treatment of CC.


Cervical Cancer; Single-chain Antibody; Linker; Homologous Modeling; Similarity Algorithm.

Cite and Share

J. Cheng,Q.X. Du,X.L. Zhang,Y.F. Ren,B.A. Zhang,X.D Feng. Study on the relationship between the structure and functions of anti-human cervical cancer single-chain antibody and the lengths of linkers. European Journal of Gynaecological Oncology. 2016. 37(2);171-177.


[1] Chang W.C., Li C.H., Huang S.C., Chang D.Y., Chou L.Y., Sheu

B. C.: “Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma”. Cancer, 2010, 116, 5777.

[2] Ferlay J., Parkin D.M., Steliarova-Foucher E.: “Estimates of cancer incidence and mortality in Europe in 2008”. Eur. J. Cancer, 2010, 46, 765.

[3] Karimi Z.M., Behatash N., Chiti Z., Karqar S.: “Cervical cancer and HPV vaccines in developing countries”. Asian Pac. J. Cancer Prev., 2009, 10, 969.

[4] Foldert M.R., Shih K.K., Abu-Rustum N.R., Jewell E., Kollmeier M. A., Makker V., et al.: “Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate and high-risk cervical cancer”. Gynecol. Oncol., 2013, 128, 288.

[5] Kesic V.: “Management of cervical cancer”. Eur. J. Surg. Oncol., 2006, 32, 832.

[6] Shu X.Y., Hu J.: “Tumor inhibition of recombined superantigen SEB-scFv fusion protein in vivo”. Chin. J. Exp. Surg., 2009, 26, 1743.

[7] Wang Y., Li X., Chen M.: “Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer”. J. South Med. Univ., 2006, 26, 16.

[8] Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotný J., Margolies M.N., et al.: “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fvanalogue produced in Escherichia coli”. Proc. Natl. Acad. Sci. U S A., 1988, 85, 5879.

[9] Sandee D., Tungpradabkul S., Tsukio M., Imanaka T., Takagi M.: “Construction and high cytoplasmic expression of a tumoricidal single-chain antibody against hepatocellular carcinoma”. BMC Biotechnol., 2002, 2, 16.

[10] Huhalov A., Chester K.A.: “Engineered single chain antibody fragments for radioimmunotherapy”. Nucl. Med. Mol. Imaging, 2004, 8, 279.

[11] Mukherjee S., Zhang Y.: “Proteinprotein complex structure predictions by multimeric threading and template recombination”. Structure, 2011, 19, 955.

[12] Zhang J., Chen Z.: “Analyzing influence on the conformation of single-chain antibody with the differential length of linkers”. Afr. J. Microbiol. Res., 2011, 5, 5737.

[13] Zitzmann S., Mier W., Schad A., Kinscherf R., Askoxylakis V., Krämer S., et al.: “A new prostate carcinoma binding peptide (DUP21) for tumor imaging and therapy”. Clin. Cancer Res., 2005, 11, 139.

[14] DeNardo S.J.: “Radioimmuno detection and therapy of breas cancer”. Semin. Nucl. Med., 2005, 35, 143.

[15] Perk J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al.: “Anti-HER-2 immunoliposomes: enhanced efficacy attributable to targeted delivery”. Clin. Cancer Res., 2002, 8, 1172.

[16] Kim M.K., Jeong H.J., Kao C.H., Yao Z., Paik D.S., Pie J.E., et al.: “Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications”. Nucl. Med. Bio., 2002, 29, 139.

[17] Hu Y.C., Liu Q.Z.: “The research process of technology and application of monoclone antibody”. Anhui. J. Preventive Med., 2008, 14, 116.

[18] Qin H.Y., Mao X.Y., Qiao Y.L., Li X.J., Zhao H.: “Progress in single- chain antibody”. Progress Mod. Biomed., 2001, 11, 795.

[19] Gustavsson M., Lehtio J., Denman S., Teeri T.T., Hult K., Martinelle M.: “Stable linker peptide for a cellulose binding domain-lipase fusion protein expressed in Pichiapastori”. Protein Eng., 2001, 14, 711.

[20] Le Gall F., Reusch U., Little M., Kipriyanov S.M.: “Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody”. Protein Eng. Des. Sel., 2004, 17, 357.

[21] Weisser N.E., Hall J.C.: “Applications of single-chain variable fragment antibodies in therapeutics and diagnostics”. Biotechnol. Adv., 2009, 27, 502.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time